These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 3013628

  • 21. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P.
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [Abstract] [Full Text] [Related]

  • 22. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ, Vree TB, Baars AM, van Herwaarden CL.
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [Abstract] [Full Text] [Related]

  • 23. The comparative pharmacokinetics and tissue penetration of four quinolones including intravenously administered enoxacin.
    Wise R, Lister D, McNulty CA, Griggs D, Andrews JM.
    Infection; 1986; 14 Suppl 3():S196-202. PubMed ID: 3463542
    [Abstract] [Full Text] [Related]

  • 24. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Ridgway GL, O'Hare MD, Felmingham D, Grüneberg RN.
    Drugs Exp Clin Res; 1985; 11(4):259-62. PubMed ID: 2941258
    [Abstract] [Full Text] [Related]

  • 25. The comparative in vitro activity of twelve 4-quinolone antimicrobials against enteric pathogens.
    O'Hare MD, Felmingham D, Ridgway GL, Grüneberg RN.
    Drugs Exp Clin Res; 1985; 11(4):253-7. PubMed ID: 2941257
    [Abstract] [Full Text] [Related]

  • 26. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH.
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [Abstract] [Full Text] [Related]

  • 27. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A, Ullmann U.
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [Abstract] [Full Text] [Related]

  • 28. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL, Thornsberry C, Jones RN.
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [Abstract] [Full Text] [Related]

  • 29. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL, Jones RN.
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [Abstract] [Full Text] [Related]

  • 30. [Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin].
    Dubreuil L, Devos J, Romond C, Bryskier A.
    Pathol Biol (Paris); 1985 May; 33(5):421-5. PubMed ID: 3162143
    [Abstract] [Full Text] [Related]

  • 31. Chemotherapeutic effects of ofloxacin (HOE 280) and other quinolone-carboxylic derivates in the treatment of experimental lung infections due to Klebsiella pneumoniae DT-S in mice.
    Klesel N, Limbert M, Seibert G, Winkler I, Schrinner E.
    Infection; 1986 May; 14 Suppl 1():S36-9. PubMed ID: 2937738
    [Abstract] [Full Text] [Related]

  • 32. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 33. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C, Nord CE.
    Scand J Infect Dis; 1986 Apr; 18(2):149-51. PubMed ID: 2939556
    [Abstract] [Full Text] [Related]

  • 34. Antichlamydial activity of quinolone carboxylic acids.
    Heppleston C, Richmond S, Bailey J.
    J Antimicrob Chemother; 1985 May; 15(5):645-7. PubMed ID: 3159713
    [No Abstract] [Full Text] [Related]

  • 35. Symposium on antimicrobial agents. The quinolones.
    Walker RC, Wright AJ.
    Mayo Clin Proc; 1987 Nov; 62(11):1007-12. PubMed ID: 3312850
    [Abstract] [Full Text] [Related]

  • 36. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT.
    Scand J Infect Dis Suppl; 1986 Nov; 49():115-23. PubMed ID: 3547618
    [Abstract] [Full Text] [Related]

  • 37. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S, Sparham PD, Spencer RC.
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [Abstract] [Full Text] [Related]

  • 38. Activity of AT-2266 compared with those of norfloxacin, pipemidic acid, nalidixic acid, and gentamicin against various experimental infections in mice.
    Nakamura S, Nakata K, Katae H, Minami A, Kashimoto S, Yamagishi J, Takase Y, Shimizu M.
    Antimicrob Agents Chemother; 1983 May; 23(5):742-9. PubMed ID: 6223579
    [Abstract] [Full Text] [Related]

  • 39. Comparative pharmacokinetics of new quinolones.
    Lode H, Höffken G, Prinzing C, Glatzel P, Wiley R, Olschewski P, Sievers B, Reimnitz D, Borner K, Koeppe P.
    Drugs; 1987 May; 34 Suppl 1():21-5. PubMed ID: 3481323
    [Abstract] [Full Text] [Related]

  • 40. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H, Quentin C, de Barbeyrac B, Bebear C.
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.